NBTX Nanobiotix S.A.

Nasdaq nanobiotix.com


$ 19.20 $ -0.08 (-0.41 %)    

Friday, 24-Oct-2025 15:59:56 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 19.2
$ 19.15
$ 17.00 x 5
$ 21.78 x 2
$ 18.08 - $ 19.37
$ 2.76 - $ 30.35
176,917
na
910.6M
$ 0.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nanobiotix-announces-first-data-from-cohorts-1-and-2-of-dose-escalation-part-of-phase-1-study-evaluating-jnj-1900-for-eadc-patients

Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the...

 nanobiotix-h1-eps-012-up-from-050-yoy-sales-30202m-up-from-10001m-yoy

Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(0.12) per share. This is a 76 percent increase over losses of $(0.50) p...

 nanobiotix-jj-therapy-shows-promise-in-tough-head-and-neck-cancer

Nanobiotix reported updated Phase 1 trial data for JNJ-1900 in head and neck cancer, showing strong disease control and surviva...

 reported-earlier-nanobiotix-reports-updated-phase-1-data-showing-jnj-1900-nbtxr3-plus-anti-pd-1-achieves-37-orr-and-63-dcr-in-nave-rm-hnscc-patients

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïv...

 stitch-fix-posts-q4-results-joins-transocean-mbx-biosciences-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION